41 results about "Multi drug resistant bacteria" patented technology

The invention discloses a novel compound 3,3'-(3,4-dichlorobenzylidene)-bis-4-hydroxycoumarin with a strong antibacterial effect which is optimized by transforming the structure of bishydroxycoumarin compounds, and provides a preparation method thereof, wherein the chemical structure and crystal structure are obtained. The novel compound 3,3'-(3,4-dichlorobenzylidene)-bis-4-hydroxycoumarin has an antibacterial application value in preparation of a medicine resisting staphylococcus aureus (ATCC29213), methicillin-resistant staphylococcus aureus (MRSA, XJ7502), USA300 (LAC) and vancomycin-resistant staphylococcus aureus (Mu20ATCC700699).

The present invention relates to compounds of the formula (I) that are useful antimicrobial agents and effective against a variety of multi-drug resistant bacteria:

The invention belongs to the field of pharmaceutical chemistry, and discloses pleuromutilin derivatives having alkaline side chains and a preparation method thereof. The structural formula of the pleuromutilin derivatives having alkaline side chains is shown in Formula (I), wherein R is phenylpropylamine, phenylethylamine, 4-hydroxyl-phenylethylamine, 4-methylphenylethylamine, 2-methylphenylethylamine, 4-(2-aminoethyl)pyridine, di-iso-butylmanice, thiophene-2-ethylamine, octylamine, laurylamine, cetylamine, 2-(mesyl)ethylamine or 2-(methylthio)ethylamine. The derivatives have favorable activity of inhibiting drug-resistant Staphylococcus aureus and mycoplasma, and are especially suitable to serve as a novel antibacterial drug for preventing and treating human or animal infectious diseases caused by methicillin-resistant Staphylococcus aureus or multi-drug resistant bacteria.

The present invention relates to novel phenyl oxazolidinone compounds of formula I, their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of formula I or their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of formula I and methods of using them. The compounds of the present invention are useful as antimicrobial agents, effective against a number of aerobic and/or anaerobic Gram positive and/or Gram negative pathogens such as multi drug resistant species of Staphylococcus, Streptococcus, Enterococcus, Bacterioides, Clostridia, H. influenza, Moraxella, acid-fast organisms such as Mycobacterium tuberculosis as well as Linezolid resistant species of Staphylococcus and Enterococcus.

The present disclosure provides dry powder antibiotic compositions that are effective in the treatment of bacterial infections and associated conditions. Moreover, the present disclosure provides dry powder antibiotic compositions for the treatment of bacterial infections, by multi-drug resistant bacteria, resulting in the subsequent reduction in the prevalent rates of drug resistance.

The invention discloses a synthetic method of QseC ligand derivatives capable of inhibiting bacterial virulence and an application. The QseC ligand derivatives are bacterial membrane surface protein QseC ligands and can be specifically combined with the QseC ligands and be used for retroregulation of a qseC-qseB-fliC-flhD gene pathway, thereby inhibiting the release of bacterial pathogenic virulence factors, reducing the bacterial virulence and the invasiveness during the bacterial infection and further achieving the role of controlling the harm of the bacterial infection; however, the QseC ligand derivatives do not affect normal growth and reproduction of bacteria, thereby avoiding the initiation of bacterial drug resistance pressure. The QseC ligand derivatives have the advantages of good anti-bacterial effect, low toxicity, good stability and difficult drug resistance. The QseC ligand derivatives synthesized by the optimized synthetic method of the QseC ligands and the chemical synthetic method of the derivatives thereof can be used for preparing novel broad-spectrum antibacterial drugs with resistance to multi-drug-resistant bacteria infection.

The invention belongs to the field of medicinal chemistry, and particularly relates to a pleuromutilin derivative with 2-aminothiophenol and a 1,2,3-triazole side chain, preparation and application. The pleuromutilin derivative with 2-aminothiophenol and the 1,2,3-triazole side chain is a compound of a formula 2 or a pharmaceutically acceptable salt of the compound, and a solvent compound, an enantiomer, a diastereomer and a tautomer of the compound of the formula 2 or the pharmaceutically acceptable salt of the compound or a mixture of the compound of the formula 2 or the pharmaceutically acceptable salt of the compound in any ratio, and includes a racemic mixture, and the compound has good inhibition to methicillin-resistant staphylococcus aureus activity, and is especially suitable forbeing used as a novel antibacterial drug for prevention and treatment of infectious diseases caused by human or animals or methicillin-resistant staphylococcus aureus or multi-drug resistant bacteria.(Please see the specification for the formula).

The invention provides antibacterial gold nanoparticles modified by tetrazole or derivatives thereof, and a preparation method and an application thereof. A substituted tetrazole part without antibacterial activity is connected with non-substituted gold nanoparticles without antibacterial activity, and the antibacterial gold nanoparticles are firstly applied in the antibacterial field; the obtained gold nanoparticles modified with substituted tetrazole have unexpected antibacterial effect. The synthesized gold nanoparticles have good antibacterial effect on both gram-negative bacteria and gram-positive bacteria, have broad antibacterial spectrum and can resist clinically isolated multi-drug resistant bacteria. Compared with the prior art, the gold nanoparticles are connected with mercapto-tetrazole compounds, the synthetic method adopts one-step synthesis in an aqueous phase, and the raw materials used in the synthesis are green and environmentally friendly.

Fulvic acid as the active ingredient is used in the treatment or inhibition of mutti-drug resistant bacteria, in particular NDM-1 bacteria producing carbapenemase or extended- spectrum beta-lactamase (ES8L) resistant bacteria. The multi-drug resistant bacteria may be gram negative bacteria including, but not limited to, Klebsiella pneumoniae or Escherichia coli.. The fuivic acid can be provided in combination with one or more antibiotics from the class of carbapenems or polymyxin antibiotics.

The invention discloses an external traditional Chinese medicinal lotion for treating infective wound caused by multi-drug resistant bacteria. In accordance with the pathogenesis of multi-drug resistant infective wound, the external lotion disclosed by the invention is prepared from the following traditional Chinese medicines which are capable of promoting blood circulation and removing stasis, clearing away heat and eliminating dampness, removing necrotic tissue and promoting generation of new tissue: thymifolious euphorbia herb, fortune silene herb with root, commen bomhax flower, root or bark of gluey litse, ophiorrhiza japonica, Japanese conehead herb, common squill bulb, circaeashape loosestrife herb and nipponian greenbrier rhizome and root. Upon clinical tests, total effective rate is 95%; and the external lotion is free from cross infection and is significant in curative effect.

Disclosed is pollution-free functional water with deodorization activity and sterilization activity against multi-drug resistant bacteria. In the present invention, the functional water is prepared by treating a solution which contains mixture of pulverized molasses, soybean and bamboo through decomposition tank, a first precipitation tank, a bio-tank, a second precipitation tank and filter. Also, disclosed in a method for preparing the functional water.

Novel benzoxazine oxazolidinone compounds, preparation methods and uses thereof are disclosed, which belong to the field of pharmacy. More specifically, novel benzoxazine oxazolidinone compounds represented by the following general formula (I), preparation methods and uses thereof in preparing medicament for treating infectious diseases, especially infectious diseases caused by multi-drug resistant bacteria, are disclosed.

The invention discloses a compound capable of effectively inhibiting or killing bacterial microorganisms. The compound has a structural general formula shown as the formula I (please see the formula in the description). Pharmacodynamic experiments prove that the compound can effectively inhibit or kill the broad-spectrum and multi-drug resistant staphylococcus aureus, streptococcus pneumoniae and staphylococcus aureus and is expected to be developed into a novel effective antibacterial drug with new targets.

The invention discloses a cyclic peptide resistant to multi-drug resistant bacteria. The cyclic peptide resistant to the multi-drug resistant bacteria is characterized in that the amino acid sequenceis any of CPeptide-A, CPeptide-B, CPeptide-C and CPeptide-D, and the antibacterial cyclic peptide is obtained through cyclization of amido bonds formed by amino groups and carboxy groups of head and tail amino acids of any of the amino acid sequence. The four novel artificially designed cationic antibacterial peptides can be synthesized by adopting an Fmoc solid-phase chemical method, the operability is strong, and the cost is low. The cationic antibacterial peptides have broad spectrum killing activity against multidrug-resistant acinetobacter baumannii, have stronger bactericidal activity than natural antimicrobial peptides, and have no toxic effect on animal and plant cells.

The invention provides a method and system for synchronously detecting the number of cases infected with multi-drug-resistant bacteria based on MapReduce and big data management. Based on the MapReduce framework, the parallel computing capability of a machine in a distributed system is utilized, the task of calculating the number of cases infected with multi-drug-resistant bacteria in a hospital in millions and tens of millions of inpatients beyond the memory and storage limit of a server is divided into tens of millions and billions of small tasks, the small tasks are simultaneously executedon a plurality of machines, and intermediate output results of the small tasks are summarized to generate a final result. According to the invention, massive parallel computing can be carried out on big data of millions, tens of millions and hundred millions of inpatients according to various calibers such as provincial and municipal areas, hospital levels, hospital beds, comprehensive and specialized departments, publicity and camp, all types of infections related to the multi-drug-resistant bacteria are managed, accurate statistics of the number of cases infected with the multi-drug-resistant bacteria in the hospital is achieved, hospital infection is integrally evaluated, and overall prevention, control and management of hospital infection of the multi-drug-resistant bacteria are achieved.

The invention provides a Chinese medicinal external cleaning agent for treating infectious wounds caused by multi-drug-resistant bacteria, which relates to the field of Chinese medicinal compositionsand comprises the following raw materials in parts by weight: rhubarb 12-16 parts, Angelica 6-9 parts, astragalus root 7-10 parts, pearl powder 8-14 parts, calamine 7-11 parts, bezoar 7-10 parts, pseudo-ginseng 5-10 parts, nail beads 3-10 parts, Phellodendron amurense 7-10 parts, dragon's blood 5-12 parts, blood charcoal 9-14 parts, honeysuckle 11-14 parts, and rhizoma Polygoni Cuspidati 3-9 parts, Patrinia villosa 2-10 parts, water extract of milk perfume 5-9 parts. The external cleaning agent prepared by the invention can accelerate the recovery speed of the infectious wound, help the granulation tissue to grow and promote the wound healing, and assist the patient to recover as soon as possible.

The invention discloses an aggregation infection route monitoring method, device and equipment and a storage medium, and the method comprises the steps: querying the identity information of a user who initiates an infection route locking request, and determining the user authority of the user according to the identity information, inquiring hospitalization process information, transfer information, drug-resistant bacteria inspection information, bed distribution information and medical staff nursing information of the patient pointed by the infection route locking request; determining a zero case; and determining and outputting a propagation relation path according to the bacteria detection date and the occurrence time of the time-space relationship by combining all the multi-drug-resistant bacteria detection cases with the time-space relationship according to the zero case. The method, the device, the equipment and the storage medium have the beneficial effects that the zero case is determined according to the hospitalization process information, the transfer information, the drug-resistant bacteria test information, the bed distribution information and the nursing information of the medical staff of the patient, so that the hospitalization aggregation event infection route is quickly locked.

The invention relates to an application of bronopol and an analogue thereof in the preparation of antibacterial drugs, and belongs to the medicine filed. The chemical name of antibacterial is 2-bromo-2-nitro-1,3-propylene glycol, and the chemical name of the analogue of bronopol is 2,2-dibromo-2-nitroethanol. Bronopol and analogue thereof have a very good inhibition activity on bacteria, and drug resistant bacteria, especially multi-drug resistant bacteria, and can be used to treat a plurality of common bacterial infections of livestock and poultry.

The present invention relates to compounds of the Formula I that are useful antimicrobial agents and effective against a variety of multi-drug resistant bacteria.

The invention discloses an electrode modified based on graphene oxide, gold nanotubes and locked nucleic acid probes and its preparation method and application. The electrode is a gold electrode modified by graphene oxide, gold nanotubes and locked nucleic acid probes and signal amplification Probe composition, with this electrode as working electrode, platinum electrode as counter electrode, saturated calomel electrode as reference electrode, the PBS solution containing 2mmol/L K3Fe(CN)6-K4Fe(CN)6 and 5mmol/L KCl is The test base solution is used to build an electrochemical biosensor, which can quickly, specifically and sensitively detect the NDM-1 gene, and provide a simple, fast, sensitive and specific tool for the detection of multi-drug resistant bacteria, which has a good market value.

The invention discloses a cyclopeptide capable of resisting multiple drug resistance bacteria and application of the cyclopeptide. The cyclopeptide is characterized in that the amino acid sequence of the cyclopeptide is any one of the following six types: R-R-W-W-W-R, R-W-R-W-R-W, R-R-W-W-W-R-R, R-R-W-W-R-R-W, R-R-W-W-W-W-R-R, and R-R-W-W-R-R-R-W. The antibacterial cyclopeptide is obtained by cyclizing any one of the above amino acid sequences. The invention provides six novel antibacterial peptides with artificially designed cations. The antibacterial peptides can be synthesized by adopting an Fmoc solid-phase chemical method. The cationic antibacterial peptide has broad-spectrum killing activity on multi-drug-resistant acinetobacter baumannii, staphylococcus aureus and escherichia coli, has no toxic effect on animal and plant cells, and is high in operability and low in cost.